Nonmelanoma cutaneous head and neck cancer and merkel cell carcinoma: Current concepts, advances, and controversies

Journal of Clinical Oncology

Volumn 33, Issue 29, 2015, Pages 3338-3345

  Porceddu, Sandro V ^a   Veness, Michael J ^b,c   Guminski, Alexander ^c,d  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Westmead Cancer Care Centre   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; SONIDEGIB; VISMODEGIB;

ADVANCED CANCER; BASAL CELL CARCINOMA; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL FEATURE; FOLLOW UP; HEAD AND NECK CANCER; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPH NODE METASTASIS; MERKEL CELL TUMOR; NON MELANOMA SKIN CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOLAR RADIATION; SQUAMOUS CELL CARCINOMA; SYSTEMIC THERAPY; TOPICAL TREATMENT; ULTRAVIOLET RADIATION; CARCINOMA, BASAL CELL; CARCINOMA, MERKEL CELL; EVIDENCE BASED MEDICINE; HEAD AND NECK NEOPLASMS; MULTIMODALITY CANCER THERAPY; ONCOLOGY; PROGNOSIS; SKIN NEOPLASMS; TRENDS;

CARCINOMA, BASAL CELL; CARCINOMA, MERKEL CELL; COMBINED MODALITY THERAPY; EVIDENCE-BASED MEDICINE; HEAD AND NECK NEOPLASMS; HUMANS; MEDICAL ONCOLOGY; PROGNOSIS; SKIN NEOPLASMS;

EID: 84944232987     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.60.7333     Document Type: Review

References (73)

1. Rogers HW, Weinstock MA, Harris AR, et al: Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol 146: 283- 287, 2010
2. Alam M, Ratner D: Cutaneous squamous-cell carcinoma. N Engl J Med 344: 975-983, 2001
3. Brantsch KD, Meisner C, Schönfisch B, et al: Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: A prospective study. Lancet Oncol 9: 713-720, 2008
4. National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology: Basal cell and squamous cell skin cancers (version 2.2012). www .nccn.org/professionals/physician-gls/f-guidelines.asp
5. Lindelof B, Sigurgeirsson B, Gäbel H, et al: Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol 143: 513-519, 2000
6. Heath M, Jaimes N, Lemos B, et al: Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: The AEIOU features. J Am Acad Dermatol 58: 375-381, 2008
7. Soyer HP, Rigel, et al: Actinic keratosis, basal cell carcinoma and squamous cell carcinoma, in Bolognia JL, Jorizzo JL, Schaffer JV (eds): Dermatology (ed 3). London, United Kingdom, Elsevier, 2012, pp 1773-1794
8. Australian Cancer Network, Cancer Council Australia: Clinical practice guide: Basal cell carcinoma, squamous cell carcinoma (and related lesions)-A guide to clinical management in Australia. http: //www.cancer.org .au/content/pdf/HealthProfessionals/ClinicalGuidelines/ Basal-cell-carcinoma-Squamous-cell-carcinoma-Guide-Nov-2008-Final-with-Corrigendums.pdf
9. Chen AC, Halliday GM, Damian DL: Nonmelanoma skin cancer: Carcinogenesis and chemoprevention. Pathology 45: 331-341, 2013
10. Green A, Leslie D, Weedon D: Diagnosis of skin cancer in the general population: Clinical accuracy in the Nambour survey. Med J Aust 110: 880-884, 1988
11. Edge SB, Byrd DR, Comptom CC, et al: (eds): AJCC Cancer Staging Manual (ed 7). New York, NY, Springer, 2010
12. Sobin L, Gospodarowicz M, Wittekind C (eds): UICC International Union Against Cancer TNM Classification of Malignant Tumors (ed 7). West Sussex, United Kingdom, Wiley-Blackwell, 2009
13. Clayman GL, Lee JJ, Holsinger FC, et al: Mortality risk from squamous cell skin cancer. J Clin Oncol 23: 759-765, 2005
14. Jambusaria-Pahlajani A, Kanetsky PA, Karia PS, et al: Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and proposed alternative tumor staging system. JAMA Dermatol 149: 402-410, 2013
15. Forest VI, Clark JJ, Veness MJ, et al: N1S3: A revised staging system for head and neck cutaneous squamous cell carcinoma with lymph node metastases. Cancer 116: 1298-1304, 2010
16. Leibovitch I, Huilgol SC, Selva D, et al: Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia: Experience over 10 years. J Am Acad Dermatol 53: 253-260, 2005
17. Smeets NW, Krekels GA, Ostertag JU, et al: Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: Randomised controlled trial. Lancet 364: 1766-1772, 2004
18. Kropp L, Balamucki CJ, Morris CG, et al: Mohs resection and postoperative radiotherapy for head and neck cancers with incidental perineural invasion. Am J Otolaryngol 34: 373-377, 2013
19. Brodland DG, Zitelli JA: Surgical margins for excision of primary cutaneous squamous cell carcinoma: J Am Acad Dermatol 27: 241-248, 1992
20. Veness MJ: The important role of radiotherapy in patients with non-melanoma skin cancer and other cutaneous entities: J Med Imaging Radiat Oncol 52: 278-286, 2008
21. Cognetta AB, Howard BM, Heaton HP, et al: Superficial x-ray in the treatment of basal and squamous cell carcinomas: A viable option in select patients. J Am Acad Dermatol 67: 1235-1241, 2012
22. Khan L, Choo R, Breen D, et al: Recommendations for CTV margins in radiotherapy planning for non melanoma skin cancer. Radiother Oncol 104: 263-266, 2012
23. Chitwood K, Etzkorn J, Cohen G: Topical and intralesional treatment of nonmelanoma skin cancer: Efficacy and cost implications. Dermatol Surg 39: 1306-1316, 2013
24. McGillis ST, Fein H: Topical treatment strategies for non-melanoma skin cancer and precursor lesions. Semin Cutan Med Surg 23: 174-183, 2004
25. Veness MJ, Porceddu S, Palme CE, et al: Cutaneous head and neck squamous cell carcinoma metastatic to parotid and cervical lymph nodes. Head Neck 29: 621-631, 2007
26. O'Hara J, Ferlito A, Takes RP, et al: Cutaneous squamous cell carcinoma of the head and neck metastasizing to the parotid gland: A review of current recommendations. Head Neck 33: 1789- 1795, 2011
27. Kirke DN, Porceddu S, Wallwork BD, et al: Pathologic occult neck disease in patients with metastatic cutaneous squamous cell carcinoma to the parotid. Otolaryngol Head Neck Surg 144: 549-551, 2011
28. Ross AS, Schmults CD: Sentinel lymph node biopsy in cutaneous squamous cell carcinoma: A systematic review of the English literature. Dermatol Surg 32: 1309-1321, 2006
29. Veness MJ, Morgan GJ, Palme CE, et al: Surgery and adjuvant radiotherapy in patients with cutaneous head and neck squamous cell carcinoma metastatic to lymph nodes: Combined treatment should be considered best practice. Laryngoscope 115: 870-875, 2005
30. Ebrahim A, Clark JR, Lorincz BB, et al: Metastatic head and neck cutaneous squamous cell carcinoma: Defining a low-risk patient. Head Neck 34: 365-370, 2012
31. Cooper JS, Pajak TF, Forastiere AA, et al: Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous cell carcinoma of the head and neck. N Engl J Med 350: 1937-1944, 2004
32. Bernier J, Domenge C, Ozsahin M, et al: Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350: 1945-1952, 2004
33. Cranmer LD, Engelhardt C, Morgan SS: Treatment of unresectable and metastatic cutaneous squamous cell carcinoma. Oncologist 15: 1320-1328, 2010
34. Nottage M, Francesconi A, Houston K, et al: A prospective study investigating the impact of definitive chemoradiation in locoregionally advanced squamous cell carcinoma of the skin. J Clin Oncol 30: 549s, 2012 (abstr 8538)
35. Maubec E, Petrow P, Scheer-Senyarich I, et al: Phase II study of cetuximab as first-line singledrug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 29: 3419-3426, 2011
36. Foote MC, McGrath M, Guminski A, et al: Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma. Ann Oncol 25: 2047-2052, 2014
37. Carter JB, Johnson MM, Chua TL, et al: Outcomes of primary cutaneous squamous cell carcinoma with perineural invasion: An 11-year cohort study. JAMA Dermatol 149: 35-41, 2013
38. Gandhi MR, Panizza B, Kennedy D: Detecting and defining the anatomic extent of large nerve perineural spread of malignancy: Comparing "targeted" MRI with the histologic findings following surgery. Head Neck 33: 469-475, 2011
39. Jackson JE, Dickie GJ, Wiltshire KL, et al: Radiotherapy for perineural invasion in cutaneous head and neck carcinomas: Toward a risk-adapted treatment approach. Head Neck 31: 604-610, 2009
40. Jambusaria-Pahlajani A, Miller CJ, Quon H, et al: Surgical monotherapy versus surgery plus adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma: A systematic review of outcomes. Dermatol Surg 35: 574-585, 2009
41. Mendenhall WM, Ferlito A, Takes RP, et al: Cutaneous head and neck basal and squamous cell carcinomas with perineural invasion. Oral Oncol 48: 918-922, 2012
42. Panizza B, Solares CA, Redmond M, et al: Surgical resection for clinical perineural invasion from cutaneous squamous cell carcinoma of the head and neck. Head Neck 34: 1622-1627, 2012
43. Balamucki CJ, Mancuso AA, Amdur RJ, et al: Skin cancer of the head and neck with perineural invasion. Am J Otolaryngol Head Neck Med Surg 33: 447-454, 2012
44. Tomaszewski JM, Gavriel H, Link E, et al: Aggressive behavior of cutaneous squamous cell carcinoma with chronic lymphocytic leukemia. Laryngoscope 124: 2043-2048, 2014
45. Epstein E: How accurate is the visual assessment of basal carcinoma margins? Br J Dermatol 89: 37-43, 1973
46. Cho M, Gordon L, Rembielak A, et al: Utility of radiotherapy for treatment of basal cell carcinoma: A review. British J Dermatol 171: 968-973, 2014
47. Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al: Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 366: 2180-2188, 2012
48. Sekulic A, Migden MR, Oro AE, et al: Efficacy and safety of vismodegib in advanced basal cell carcinoma. N Engl J Med 366: 2171-2179, 2012
49. Migden MR, Guminski AD, Gutzmer R, et al: Randomized, double-blind study of Sonidegib (LDE225) in patients (pts) with locally advanced (La) or metastatic (m) basal-cell carcinoma (BCC). J Clin Oncol 32: 573s, 2014 (suppl 15s; abstr 9009a)
50. Moeholt K, Aagaard H, Pfeiffer P, et al: Platinum-based cytotoxic therapy in basal cell carcinoma: A review of the literature. Acta Oncol 35: 677-682, 1996
51. Krähn G, Leiter U, Kaskel P, et al: Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer Eur J Cancer 37: 251-259, 2001
52. Feng H, Shuda M, Chang Y, et al: Clonal integration of polyomavirus in human Merkel cell carcinoma. Science 319: 1096-1100, 2008
53. Amber K, McLeod MP, Nouri K: The Merkel cell polyomavirus and its involvement in Merkel cell carcinoma. Dermatol Surg 39: 232-238, 2013
54. Aaron ST, Canavan T, Yu SS: Organ transplant recipients with Merkel cell carcinoma have reduced progression-free, overall and disease-specific survival independent of stage at presentation. J Am Acad Dermatol 71: 684-690, 2014
55. Garneski KM, Warcola AH, Feng Q: Merkel cell polyomavirus is more frequently present in North American than Australian Merkel cell carcinoma tumors. J Invest Dermatol 129: 246-248, 2009
56. Schrama D, Peitsch WK, Zapatka M, et al: Merkel cell polyomavirus status is not associated with clinical course of Merkel cell carcinoma. J Invest Dermatol 131: 1631-1638, 2011
57. Paik JY, Hall G, Clarkson A, et al: Immunohistochemistry for Merkel cell polyomavirus is highly specific but not sensitive for the diagnosis of Merkel cell carcinoma in the Australian population. Hum Pathol 42: 1385-1390, 2011
58. Howle JR, Hughes TM, Gebski V, et al: Merkel cell carcinoma: An Australian perspective and the importance of addressing the regional lymph nodes in clinically node-negative patients. J Am Acad Dermatol 67: 33-40, 2012
59. Lemos BD, Storer BE, Iyer JG, et al: Pathological nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: Analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol 63: 751-761, 2010
60. Foote M, Veness M, Zarate D, et al: Merkel cell carcinoma: The prognostic implications of an occult primary in stage IIIB (nodal) disease. J Am Acad Dermatol 67: 395-399, 2012
61. Asgari MA, Sokil MM, Warton EM, et al: Effect of host, diagnostic, and treatment variables on outcomes in a large cohort with Merkel cell carcinoma. JAMA Dermatol 150: 716-723, 2014
62. Afanasiev OK, Yelistratova L, Miller N, et al: Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers. Clin Cancer Res 19: 5351-5360, 2013
63. Dowlatshahi M, Huang V, Gehad AE, et al: Tumor-specific T cells in human Merkel cell carcinomas: A possible role for Tregs and T-cell exhaustion in reducing T-cell responses. J Invest Dermatol 133: 1879-1889, 2013
64. Siva S, Byrne K, Seel M, et al: 18FDG PET provides high-impact and powerful prognostic stratification in the staging of Merkel cell carcinoma: A 15-year institutional experience. J Nucl Med 54: 1223-1229, 2013
65. Mojica P, Smith D, Ellenhorn JD: Adjuvant radiation therapy is associated with improved survival in Merkel cell carcinoma of the skin. J Clin Oncol 25: 1043-1047, 2007
66. Allen PJ, Bowne WB, Jaques DP, et al: Merkel cell carcinoma: Prognosis and treatment of patients from a single institution. J Clin Oncol 23: 2300-2309, 2005
67. Foote M, Harvery J, Porceddu S, et al: Effect of radiotherapy dose and volume on relapse in Merkel cell cancer of the skin. Int J Radiat Oncol Bio Phys 77: 677-684, 2010
68. Finnigan R, Hruby G, Wratten C, et al: The impact of preradiation residual disease volume on time to locoregional failure in cutaneous Merkel cell carcinoma-A TROG substudy. Int J Radiat Oncol Biol Phys 86: 91-95, 2013
69. Schwartz JL, Griffith KA, Lowe L, et al: Features predicting sentinel lymph node positivity in Merkel cell carcinoma. J Clin Oncol 29: 1036-1041, 2011
70. Poulsen M, Rischin D, Walpole E, et al: Highrisk Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: A Trans-Tasman Radiation Oncology Group study- TROG 96: 07. J Clin Oncol 21: 4371-4376, 2003
71. Poulsen MG, Rischin D, Porter I, et al: Does chemotherapy improve survival in high-risk stage I and II Merkel cell carcinoma of the skin? Int J Radiat Oncol Biol Phys 64: 114-119, 2006
72. Bhatia S, Iyer JG, Storer B, et al: Adjuvant radiation therapy and chemotherapy in Merkel cell carcinoma: Survival analysis of 6908 cases from the National Cancer Data Base. J Clin Oncol 32: 575s, 2014 (suppl 15s; abstr 9014)
73. Tai PT, Yu E, Winquist E, et al: Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: Case series and review of 204 cases. J Clin Oncol 18: 2493-2499, 2000